What is the O‑RADS (Ovarian‑Adnexal Reporting and Data System) classification and its management recommendations for each category?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

O-RADS (Ovarian-Adnexal Reporting and Data System) Classification

O-RADS is a standardized 6-category risk stratification system (0-5) that assigns malignancy risk to ovarian and adnexal lesions based on ultrasound features, with specific management recommendations for each category to optimize patient outcomes and reduce unnecessary surgeries. 1

The Six O-RADS Categories

O-RADS 0: Incomplete Evaluation (Risk: N/A)

  • Lesion characteristics: Technical limitations prevent adequate assessment (bowel gas, large size, patient intolerance of transvaginal imaging)
  • Management: Repeat ultrasound or alternative imaging (MRI) 1

O-RADS 1: Normal Ovary (Risk: 0%)

  • Lesion characteristics: Physiologic findings in premenopausal women only
    • Follicle: Simple cyst <3 cm
    • Corpus luteum: Thick-walled cyst <3 cm with crenulated margins, internal echoes, peripheral flow
  • Management: No follow-up needed 1

O-RADS 2: Almost Certainly Benign (Risk: <1%)

  • Lesion characteristics:
    • Simple cysts 3-10 cm
    • Classic benign lesions <10 cm (hemorrhagic cyst, dermoid, endometrioma, paraovarian cyst, peritoneal inclusion cyst, hydrosalpinx)
    • Non-simple unilocular cysts <10 cm with smooth inner walls
  • Management:
    • Premenopausal: No follow-up for cysts <3 cm; 8-12 week follow-up for 3-5 cm cysts; yearly follow-up for 5-10 cm cysts
    • Postmenopausal: 8-12 week follow-up or ultrasound specialist/MRI evaluation 1

O-RADS 3: Low Risk (Risk: 1% to <10%)

  • Lesion characteristics:
    • Unilocular cysts ≥10 cm (simple or non-simple)
    • Classic benign lesions ≥10 cm
    • Unilocular cysts with irregular inner wall <3 mm height
    • Multilocular cysts <10 cm with smooth walls, color score 1-3
    • Solid smooth lesions with color score 1
  • Management: Gynecologist management; ultrasound specialist or MRI evaluation recommended for optimal characterization 1

Key point: Over 90% of O-RADS 3 lesions are benign, so gynecologic oncology consultation is not needed 1

O-RADS 4: Intermediate Risk (Risk: 10% to <50%)

  • Lesion characteristics:
    • Multilocular cysts ≥10 cm with smooth walls, color score 1-3
    • Multilocular cysts (any size) with smooth walls, color score 4
    • Multilocular cysts with irregular walls/septa (any color score)
    • Unilocular cysts with 0-3 papillary projections (any color score)
    • Multilocular-solid lesions with color score 1-2
    • Solid smooth lesions with color score 2-3
  • Management: Gynecologist with gynecologic oncology consultation OR direct gynecologic oncology referral; ultrasound specialist or MRI evaluation strongly recommended 1

Critical consideration: Menopausal status, ultrasound specialist evaluation, MRI, and CA-125 may guide whether general gynecologist or gynecologic oncologist manages the case 1

O-RADS 5: High Risk (Risk: ≥50%)

  • Lesion characteristics:
    • Unilocular cysts with ≥4 papillary projections (any size, any color score)
    • Multilocular-solid lesions with color score 3-4
    • Solid smooth lesions with color score 4
    • Solid irregular lesions (any size, any color score)
    • Ascites and/or peritoneal nodules
  • Management: Direct referral to gynecologic oncologist 1

Critical Governing Principles

Multiple lesions: Each lesion is scored separately; management is driven by the highest O-RADS score 1

Menopausal status matters: Postmenopause is defined as amenorrhea ≥1 year; this significantly affects management recommendations 1

Size measurement: Use the largest diameter regardless of imaging plane 1

Color score integration: Color Doppler assessment (scores 1-4) becomes critical starting at O-RADS 3 and is essential for distinguishing O-RADS 4 from O-RADS 5 lesions 1

High-risk patients: The system applies to average-risk patients; those with BRCA mutations or significant family history require modified management 1

Common Pitfalls to Avoid

Do not use CA-125 routinely for risk stratification. Elevated CA-125 in premenopausal women with intermediate-risk lesions may falsely suggest malignancy (e.g., endometriosis), while normal CA-125 in postmenopausal women with O-RADS 4-5 lesions provides false reassurance 1

Ascites with O-RADS 1-2 lesions: Consider alternative etiologies for ascites (non-ovarian malignancy, cirrhosis, heart failure) 1

Classic benign descriptors take precedence: When specific features of hemorrhagic cyst, dermoid, or endometrioma are present, use these diagnoses rather than generic descriptors 1

Performance Characteristics

The O-RADS system prioritizes sensitivity over specificity to avoid missing ovarian cancer in average-risk populations, accepting higher false-positive rates to ensure appropriate referral of malignancies 1. Validation studies demonstrate high sensitivity for malignancy detection with O-RADS 4 as the optimal cutoff 2, 3. The 2022 update refined descriptors to improve specificity while maintaining diagnostic performance 2.

References

3
Research

The Ovarian/Adnexal Reporting and Data System for Ultrasound: From Standardized Terminology to Optimal Risk Assessment and Management.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 2023

Related Questions

What is the new adnexal lesion assessment model, its risk scoring system, and the recommended management for each risk category?
For ovarian lesions, which Ovarian Imaging Reporting and Data System (O‑RADS) categories require contrast‑enhanced CT for staging and surgical planning, and which categories do not require CT?
Is the American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 280 triage criteria still used for adnexal lesion assessment?
Is it standard practice for radiologists to use the term “a few” to describe multiple findings on an MRI, such as a few small follicles or microcysts, and does the wording depend on the type of finding?
What postoperative care should be provided after an exploratory laparoscopy with removal of an ovarian mass?
In a patient with renal failure (creatinine clearance <30 mL/min), how should Robaxin (methocarbamol) be used and what dose adjustments are recommended?
What is the summary of the patient's case?
Which muscle relaxant is safest for patients with renal failure on dialysis?
What is the clinical significance of a persistent enlarged axillary lymph node lasting >18 months in a healthy 25-year-old woman?
Is psoas muscle pain a common issue in individuals with quadriplegia?
According to the Brazilian Ministry of Health protocol, if a mother was adequately treated for syphilis during pregnancy, had a negative Venereal Disease Research Laboratory (VDRL) test during pregnancy but the VDRL titer rose to 1:4 at delivery, is she still considered adequately treated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.